Clinical Trials Sponsored by Medicines Development for Global Health

Total 1660 results

Medicines Development for Global Health

Completed

Dose-finding Study of Moxidectin for Treatment of Scabies

Scabies

Australia, Austria, France
Medicines Development for Global Health

Active, not recruiting

Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis

Onchocerciasis

Congo, The Democratic Republic of the
Medicines Development for Global Health

Completed

A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

Onchocerciasis

Ghana
Medicines Development for Global Health

Recruiting

Efficacy and Safety Study of Moxidectin in Adults With Scabies

Scabies

United States, Honduras
Medicines Development for Global Health

Recruiting

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

Onchocerciasis

Côte D'Ivoire, Congo, The Democratic Republic of the
Medicines Development for Global Health

Completed

Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers

QT Effects in Healthy Volunteers

United States
Medicines Development for Global Health
World Health Organization

Completed

Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection

Onchocerciasis

Ghana
Medicines Development for Global Health
World Health Organization

Completed

Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection

Onchocerciasis

Congo, The Democratic Republic of the, Ghana, Liberia
Global Alliance for TB Drug Development

Recruiting

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis

Drug Sensitive Tuberculosis | Pulmonary Tuberculosis | Pulmonary TB

Philippines, South Africa, Tanzania, Georgia, Uganda
Global Alliance for TB Drug Development

Active, not recruiting

A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers (PaSEM)

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Tuberculosis, MDR | Drug-Resistant Tuberculosis

Georgia, South Africa
Global Alliance for TB Drug Development

Completed

Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis (ZeNix)

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Extensively Drug-Resistant Tuberculosis | Tuberculosis, MDR | XDR-TB | Pre-XDR-TB

South Africa, Russian Federation, Georgia, Moldova, Republic of
Global Alliance for TB Drug Development

Completed

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis Infection

United States
Global Alliance for TB Drug Development

Completed

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis Infection

United States
Global Alliance for TB Drug Development

Completed

A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis

Pulmonary Tuberculosis

South Africa
Global Alliance for TB Drug Development

Completed

Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)

Pulmonary Tuberculosis

South Africa
Global Alliance for TB Drug Development

Completed

PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis

Pulmonary Tuberculosis

South Africa
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)

Pulmonary Tuberculosis
Global Alliance for TB Drug Development

Terminated

A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis
Global Alliance for TB Drug Development

Completed

PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (NC-005)

Tuberculosis

Tanzania, South Africa, Uganda
Global Alliance for TB Drug Development

Completed

Shortening Treatment by Advancing Novel Drugs (STAND)

Tuberculosis, Pulmonary, Drug Sensitive | Tuberculosis, Pulmonary, Multi Drug-resistant

South Africa, Zambia, Georgia, Philippines, Kenya, Malaysia, Tanzania, Uganda
Global Alliance for TB Drug Development

Completed

A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects. (CL-004)

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

Pulmonary Tuberculosis

Tanzania, South Africa
Global Alliance for TB Drug Development

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

Tuberculosis | Tuberculosis, Pulmonary

United States
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)

Pulmonary Tuberculosis

South Africa
Global Alliance for TB Drug Development

Completed

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-003)

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Tuberculosis, MDR | Drug-Resistant Tuberculosis

Tanzania, Georgia, Russian Federation, Brazil, Malaysia, Philippines, South Africa, Uganda
Global Alliance for TB Drug Development

Completed

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Tuberculosis | Tuberculosis, Pulmonary

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
Global Alliance for TB Drug Development

Completed

A Study in Two Panels of Healthy Adult Participants to Assess Single-Dose Immediate-Release and Single-Dose Dispersible Formulations of Pretomanid

Multi-drug Resistant Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009) (CL-009)

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

Tuberculosis | Tuberculosis, Pulmonary

United States
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)

Pulmonary Tuberculosis

South Africa
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (NC-003)

Pulmonary Tuberculosis

South Africa
National Center for Global Health and Medicine,...

Active, not recruiting

Risk Stratification of COVID-19 Using Urine Biomarkers

Covid19 | Urine | Acute Respiratory Failure With Hypoxia | Biomarker

United States, Brazil, Denmark, Japan, Philippines
National Center for Global Health and Medicine,...

Unknown

Utility of Urinary beta2 Microglobulin as an Early Marker of Renal Dysfunction in Vietnamese HIV-Infected Patients

HIV Infection | Renal Function Disorder | Renal Tubular Disorder
National Center for Global Health and Medicine,...

Completed

Safety Study of Maraviroc's Effect on Human Osteoclasts (MVC-Bone)

HIV Infections | AIDS

Japan
Barcelona Institute for Global Health

Completed

Maternal Diet, Body Mass Index Trajectories and Cardiometabolic Risk in Early Childhood

Growth | Childhood Obesity | Cardiometabolic Risk
Barcelona Institute for Global Health

Completed

Fatty Acids and Attention Deficit and Hyperactivity Disorder Symptoms

Attention Deficit Hyperactivity Disorder | Child Behavior Problem | Fatty Acid Deficiency
Barcelona Institute for Global Health

Completed

PHENOTYPE. Therapeutic Study in Barcelona

Poor Mental Health | Natural Outdoor Environments
Barcelona Institute for Global Health

Completed

Pregnant Women for Malaria Surveillance (MiPMon)

P. Falciparum
Medicines Development for Global Health
Imperial College London; Phillip T. and Susan M. Ragon Foundation

Terminated

A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People

HIV Infections

United Kingdom
The Task Force for Global Health
United States Agency for International Development (USAID)

Completed

A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali (LeDoxy-Mali)

Lymphedema | Lymphatic Filariasis | Filariasis

Mali
The Task Force for Global Health
United States Agency for International Development (USAID)

Completed

A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India (LeDoxy-India)

Lymphedema | Lymphatic Filariasis | Filariasis

India
The Task Force for Global Health
United States Agency for International Development (USAID)

Completed

A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka (LeDoxy-SL)

Lymphedema | Lymphatic Filariasis | Filariasis

Sri Lanka
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R)

Diabetes Mellitus, Type 2 | Albuminuria

Australia, France, Italy, Poland, Ukraine, United Kingdom, United States, China, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Malaysia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Puerto... and more
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)

Diabetes Mellitus, Type 2 | Diabetic Nephropathy

United States, Canada, France, Germany, Poland, Ukraine, United Kingdom, China, Taiwan, Spain, Argentina, Colombia, Mexico, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Japan, Australia, Korea, Republic of, Chile, New Zealand and more
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)

Cardiovascular Diseases | Diabetes Mellitus, Type 2 | Risk Factors

United States, Australia, Poland, Ukraine, United Kingdom, Belgium, Germany, France, Spain, Argentina, Colombia, Israel, Mexico, India, Canada, Netherlands, Sweden, Malaysia, New Zealand, Estonia, Russian Federation, Hungary, Norway, ... and more

Clinical Trials Sponsored by Medicines Development for Global Health

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations